Cargando…

Lipoprotein(a)

Lipoprotein(a) – Lp(a) – is an hepatically synthesized lipoprotein, structurally similar to low-density-lipoprotein, and an important marker for cardiovascular risk. Lp(a) plasma concentrations are genetically determined and can hardly be modified by diet, exercise or oral drugs. Lp(a) concentration...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reuser, Annika, Koenig, Wolfgang, Laufs, Ulrich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2022
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668486/ https://www.ncbi.nlm.nih.gov/pubmed/36323326 http://dx.doi.org/10.1055/a-1516-2701

Ejemplares similares

Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges
por: Packard, Chris, et al.
Publicado: (2021)

Association of medication adherence and depression with the control of low-density lipoprotein cholesterol and blood pressure in patients at high cardiovascular risk
por: Katzmann, Julius L, et al.
Publicado: (2018)

Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins
por: Fox, Kathleen M., et al.
Publicado: (2017)

Ambient Air Pollution and Lipoprotein-Associated Phospholipase A(2) in Survivors of Myocardial Infarction
por: Brüske, Irene, et al.
Publicado: (2011)

Lipoprotein apheresis in the management of severe hypercholesterolemia and of elevation of lipoprotein(a): current perspectives and patient selection
por: Julius, Ulrich
Publicado: (2016)

Genotype-phenotype: correlations and emerging spectrum
por: Reuser, Arnold
Publicado: (2013)

Future therapeutic options
por: Reuser, Arnold
Publicado: (2013)

Simultaneous assessment of spontaneous cage activity and voluntary wheel running in group-housed mice
por: Reuser, Annika, et al.
Publicado: (2022)

Publisher Correction: Simultaneous assessment of spontaneous cage activity and voluntary wheel running in group-housed mice
por: Reuser, Annika, et al.
Publicado: (2022)

Correction to: Response to Letter to the editors of Hopkins et al.: Effects of surgical and FFP2/N95 face masks on cardiopulmonary exercise capacity: the numbers do not add up
por: Fikenzer, Sven, et al.
Publicado: (2021)

Response to Letter to the editors referring to Fikenzer, S., Uhe, T., Lavall, D., Rudolph, U., Falz, R., Busse, M., Hepp, P., & Laufs, U. (2020). Effects of surgical and FFP2/N95 face masks on cardiopulmonary exercise capacity. Clinical research in cardiology: official journal of the German Cardiac Society, 1–9. Advance online publication. https://doi.org/10.1007/s00392-020-01704-y
por: Fikenzer, Sven, et al.
Publicado: (2020)

Correction to: Response to Letter to the editors referring to Fikenzer, S., Uhe, T., Lavall, D., Rudolph, U., Falz, R., Busse, M., Hepp, P., & Laufs, U. (2020). Effects of surgical and FFP2/N95 face masks on cardiopulmonary exercise capacity. Clinical research in cardiology: official journal of the German Cardiac Society, 1–9. Advance online publication. https://doi.org/10.1007/s00392-020-01704-y
por: Fikenzer, Sven, et al.
Publicado: (2021)

Response to Letter to the editors of Hopkins et al.: Effects of surgical and FFP2/N95 face masks on cardiopulmonary exercise capacity: the numbers do not add up
por: Fikenzer, Sven, et al.
Publicado: (2020)

Lipoprotein(a): An Enigmatic Sheep in the Lipoprotein Herd
por: Shapiro, Michael D., et al.
Publicado: (2020)

Why doesn’t high cholesterol hurt?
por: Katzmann, Julius L., et al.
Publicado: (2019)

Lipoprotein (a) concentrations, apolipoprotein (a) phenotypes, and peripheral arterial disease in three independent cohorts
por: Laschkolnig, Anja, et al.
Publicado: (2014)

Lipoprotein (a): Recent Updates on a Unique Lipoprotein
por: Saeed, Anum, et al.
Publicado: (2021)

Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
por: Katsiki, Niki, et al.
Publicado: (2023)

Current Role of Lipoprotein Apheresis in the Treatment of High-Risk Patients
por: Julius, Ulrich
Publicado: (2018)

Post-Covid-Syndrom: Wie diagnostizieren, wie behandeln?
por: Baum, Paul, et al.
Publicado: (2022)

Controversial role of plant sterol esters in the management of hypercholesterolaemia
por: Weingärtner, Oliver, et al.
Publicado: (2009)

Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk
por: Laufs, Ulrich, et al.
Publicado: (2016)

Methamphetamine‐related cardiovascular diseases
por: Schwarzbach, Valentin, et al.
Publicado: (2020)

Neue Therapiekonzepte für die Herzinsuffizienz: Studien-Highlights 2020
por: Birner, Christoph, et al.
Publicado: (2021)

Assessing the Accuracy of Estimated Lipoprotein(a) Cholesterol and Lipoprotein(a)‐Free Low‐Density Lipoprotein Cholesterol
por: Zheng, Weili, et al.
Publicado: (2022)

Beyond Lipoprotein(a) plasma measurements: Lipoprotein(a) and inflammation
por: Reyes-Soffer, Gissette, et al.
Publicado: (2021)

Profoundly Disturbed Lipoproteins in Cirrhotic Patients: Role of Lipoprotein-Z, a Hepatotoxic LDL-like Lipoprotein
por: van den Berg, Eline H., et al.
Publicado: (2022)

Activation of Lipid Mediator Formation Due to Lipoprotein Apheresis
por: Weylandt, Karsten-H., et al.
Publicado: (2019)

Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
por: Schulz, Rainer, et al.
Publicado: (2015)

HDL – Quo vadis
por: von Eckardstein, Arnold, et al.
Publicado: (2023)

How the COVID-19 pandemic can distort risk adjustment of health plan payment
por: van Kleef, Richard C., et al.
Publicado: (2021)

Higher education delays and shortens cognitive impairment. A multistate life table analysis of the US Health and Retirement Study
por: Reuser, Mieke, et al.
Publicado: (2011)

Modern Approaches to Lower Lipoprotein(a) Concentrations and Consequences for Cardiovascular Diseases
por: Korneva, Victoria A., et al.
Publicado: (2021)

Further evidence that high-density lipoprotein is a chameleon-like lipoprotein
por: Fogelman, Alan M.
Publicado: (2015)

Lipoprotein(a) Lowering—From Lipoprotein Apheresis to Antisense Oligonucleotide Approach
por: Greco, Maria Francesca, et al.
Publicado: (2020)

Phosphodiesterases 2, 3 and 4 can decrease cardiac effects of H(2)-histamine-receptor activation in isolated atria of transgenic mice
por: Neumann, Joachim, et al.
Publicado: (2021)

Gene Therapy Targeting PCSK9
por: Katzmann, Julius L., et al.
Publicado: (2022)

Collateral damage: Fear from SARS-CoV2-infection causing Takotsubo cardiomyopathy
por: Uhe, Tobias, et al.
Publicado: (2020)

PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
por: Katzmann, Julius L., et al.
Publicado: (2020)

State of the Art: Therapie mit Statinen
por: Laufs, Ulrich, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hn858fo75rtgohg96kjbi8bbct